Medicare Price Negotiations: Competitors’ Net Prices, Clinical Benefit Are ‘Starting Point’ For Initial Offer
Executive Summary
CMS chose the prices of therapeutic alternatives and these competitors’ comparative benefits as the ‘foundation and starting point’ for setting an initial offer for drugs subject to negotiation, ahead of other factors Congress laid out it could consider that are more singularly focused on the specific drug at issue.
You may also be interested in...
Medicare ‘Maximum Fair Price’ And The Importance Of Choosing The Right Therapeutic Alternatives
Biopharma industry raises alarm that Medicare might identify therapeutic comparators for drugs selected for price negotiation based mainly on costs.
A Level Playing Field? Medicare Tries To Balance Transparency, Confidentiality With Drug Price Negotiations
Drug manufacturers may want more ability to communicate about their drug price negotiation experience with Medicare than CMS is proposing, but if that jeopardizes protections for proprietary information, it may not be worthwhile.
Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem
Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.